Results for Thalassemia

Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.

Dr. Vogiatzi's research goals are to improve the health of children with gonadal disorders and understand the role of glucocorticoids, androgens, and sex steroids in health and disease.

Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.

Dr. Guerra is researching innovating therapies to treat β-thalassemia and sickle cell anemia and use lentiviruses as a tool. Her work aims to discover new biological targets that can be used to treat β-thalassemia and other forms of anemia.

Maxwell Chappell is a graduate student working on developing improved lentiviral vectors as well as the use of lentiviral vectors for the treatment of alpha-thalassemia.

Dr. Breda is developing safe, potentially curative genetic therapies for sickle cell disease and b-thalassemia.

Dr. Abdulmalik’s research interests involve hemoglobinopathies and red blood cell disorders, with a focus on sickle cell disease and beta-thalassemia.